Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients

机译：贝伐单抗联合厄洛替尼联合疗法治疗晚期遗传性平滑肌瘤病和肾细胞癌相关的肾细胞癌：韩国患者的多中心回顾性分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeHereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genetic syndrome resulting from germline mutations in fumarate hydratase. The combination of bevacizumab plus erlotinib showed promising interim results for HLRCC-associated RCC. Based on these results, we analyzed the outcome of bevacizumab plus erlotinib in Korean patients with HLRCC-associated RCC.

机译：目的遗传性平滑肌瘤病和肾细胞癌（HLRCC）是一种罕见的遗传综合征，其源于富马酸水合酶的种系突变。贝伐单抗加厄洛替尼的组合显示出与HLRCC相关的RCC有希望的中期结果。基于这些结果，我们分析了贝伐单抗联合厄洛替尼在韩国HLRCC相关RCC患者中的结果。

著录项

期刊名称 Cancer Research and Treatment : Official Journal of Korean Cancer Association
作者
Yeonjoo Choi; Bhumsuk Keam; Miso Kim; Shinkyo Yoon; Dalyong Kim; Jong Gwon Choi; Ja Young Seo; Inkeun Park; Jae Lyun Lee;
展开▼
作者单位

展开▼
年(卷),期 2019(51),4
年度 2019
页码 1549–1556
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Hereditary leiomyomatosis and renal cell carcinoma Bevacizumab Erlotinib Renal cell carcinoma Fumarate hydratase Non-clear cell;

机译：遗传性平滑肌瘤病和肾细胞癌;贝伐单抗;厄洛替尼;肾细胞癌;富马酸水合酶;非透明细胞;

相似文献

外文文献
中文文献
专利

1. Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib [J] . Srinivasan R., Su D., Stamatakis L., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第Suppla6期

机译：基于机制的遗传性平滑肌瘤病和肾细胞癌（HLRCC）和散发性乳头状肾细胞癌的靶向治疗：贝伐单抗和厄洛替尼的2期研究中期结果
2. Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures [J] . Inkeun Park, Young Sup Shim, Heounjeong Go, BMC Urology . 2019,第1期

机译：替西罗莫司和阿昔替尼治疗失败后，转移性遗传性平滑肌瘤病和肾细胞癌综合征相关的肾细胞癌对贝伐单抗加厄洛替尼的长期反应
3. Bevacizumab/erlotinib combination active in advanced renal cell carcinoma [J] . The Pharmaceutical Journal group The pharmaceutical journal . 2004,第7303期

机译：贝伐单抗/厄洛替尼联合治疗对晚期肾细胞癌有效
4. Integration of Surgery and Systemic Therapy in the Treatment of Locally Advanced and Metastatic Renal Cell Carcinoma [C] . Christopher G. Wood Genitourinary Cancers Symposium . 2011

机译：外科和全身治疗在局部晚期和转移性肾细胞癌中的整合
5. Renal Cell Carcinoma in End Stage Renal Disease Patients: An Institutional Review [D] . Nolte, Adam. 2019

机译：肾细胞癌在末期肾病患者：制度综述
6. Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures [O] . Inkeun Park, Young Sup Shim, Heounjeong Go, 2019

机译：替西罗莫司和阿昔替尼治疗失败后转移性遗传性平滑肌瘤病和肾细胞癌综合征相关的肾细胞癌对贝伐单抗加厄洛替尼的长期反应
7. Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study. [O] . Sung Han Kim, Sohee Kim, Byung-Ho Nam, 2015

机译：索拉非尼治疗韩国患者转移性肾细胞癌的疗效和安全性：回顾性多中心研究结果。

Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients

摘要

著录项

相似文献

相关主题

期刊订阅